Pharma BD Deal Intelligence
J&J to acquire ADC developer Ambrx for $2B at $28 per share gaining synthetic biology platform for next-gen ADCs.
Johnson & Johnson completed the acquisition of Ambrx Biopharma on March 7, 2024, in an all-cash merger transaction for a total equity value of approximately…
APEX-01 (NCT04662580): ARX517/JNJ-95298177, a PSMA-targeted ADC, as monotherapy or in combination with androgen-receptor pathway inhibitors in metastatic…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Johnson & Johnson acquired Ambrx Biopharma for approximately $2.0 billion ($28.00 per share) in an all-cash merger announced January 8, 2024 and completed March 7, 2024, gaining a proprietary synthetic biology technology platform for designing next-generation antibody-drug conjugates (ADCs) and clinical candidates targeting prostate cancer, breast cancer, and renal cell carcinoma. The lead asset, anti-PSMA ADC ARX517, has since been advanced under J&J nomenclature as JNJ-95298177; its first-in-human APEX-01 study (NCT04662580) was expanded to evaluate combination with androgen-receptor pathway inhibitors and is now active and not recruiting, with estimated study completion in December 2026.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Johnson & Johnson / Ambrx Biopharma Inc. (this deal) | 2024 | $2.0B | 57 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $9.0B | 96 |
| Johnson & Johnson / Centocor Inc. | 1999 | $4.9B | 92 |
| Johnson & Johnson / Cougar Biotechnology, Inc. | 2009 | $970M | 91 |
| Johnson & Johnson / Actelion Ltd | 2017 | $30.0B | 90 |
| Johnson & Johnson / Aragon Pharmaceuticals Inc. | 2013 | $1.0B | 89 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $350M | 83 |
← Browse all deals · How we score deals
More: 2024 deals · Johnson & Johnson deals · Oncology deals